At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses the value of genomic profiling for individualising and improving adjuvant therapy for breast cancer patients. More recently, multigene assays, such as the Oncotype DX® Breast Cancer Assay, are being considered in addition to classic clinicopathological tools to guide treatment decisions for breast cancer patients.
This content is supported by Genomic Health, Inc.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews